• 1
    Naltrexone hydrochloride (naltrexone hydrochloride) [package insert]. Barr Laboratories: Pomona, NY, 2003.
  • 2
    Berg BJ, Pettinati HM, Volpicelli JR. A risk-benefit assessment of naltrexone in the treatment of alcohol dependence. Drug Saf 1996;15:274282.
  • 3
    Lobmaier P, Kornør H, Kunøe N, Bjørndal A. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev 2008; 16:CD006140.
  • 4
    Wellbutrin SR (bupropion hydrochloride) [package insert]. GlaxoSmithKline: Research Triangle Park, NC, 2009.
  • 5
    Dhillon S, Yang LP, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs 2008;68:653689.
  • 6
    Stahl SM, Pradko JF, Haight BR et al. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion J Clin Psychiatry 2004;6:159166.
  • 7
    Zyban (bupropion hydrochloride) [package insert]. GlaxoSmithKline: Research Triangle Park, NC, 2009.
  • 8
    Tong EK, Carmody TP, Simon JA. Bupropion for smoking cessation: a review. Compr Ther 2006;32:2633.
  • 9
    Greenway FL, Whitehouse MJ, Guttadauria M et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009;17:3039.
  • 10
    Greenway FL, Dunayevich E, Tollefson G et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 2009;94:48984906.
  • 11
    Cone RD, Cowley MA, Butler AA et al. The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord 2001;25 (Suppl 5):S63S67.
  • 12
    Cowley MA, Smart JL, Rubinstein M et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001;411:480484.
  • 13
    Saper CB, Chou TC, Elmquist JK. The need to feed: homeostatic and hedonic control of eating. Neuron 2002;36:199211.
  • 14
    Jain AK, Kaplan RA, Gadde KM et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002;10:10491056.
  • 15
    National Institutes of Health/National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the Evidence Report. Obes Res 1998; 6 (Suppl 2):51S209S.
  • 16
    Wadden TA, Berkowitz RI, Womble LG et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353:21112120.
  • 17
    Digenio AG, Mancuso JP, Gerber RA, Dvorak RV. Comparison of methods for delivering a lifestyle modification program for obese patients: a randomized trial. Ann Intern Med 2009;150:255262.
  • 18
    Brownell KD. The LEARN Program for Weight Control, 7th edn. American Health Publishing: Dallas, 1998.
  • 19
    Knowler WC, Barrett-Connor E, Fowler SE et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393403.
  • 20
    National Heart, Lung, and Blood Institute & North American Association for the Study of Obesity. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. National Institutes of Health: Bethesda, MD, 2000.
  • 21
    Kolotkin RL, Crosby RD, Kosloski KD, Williams GR. Development of a brief measure to assess quality of life in obesity. Obes Res 2001;9:102111.
  • 22
    White MA, Whisenhunt BL, Williamson DA, Greenway FL, Netemeyer RG. Development and validation of the food-craving inventory. Obes Res 2002;10:107114.
  • 23
    Wilcox CS, Oskooilar N, Erickson JS et al. An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addict Behav 2010;35:229234.
  • 24
    Rush AJ, Carmody T, Reimitz, PE. The Inventory of Depressive Symptomatology (IDS): clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatr Res 2000;9:4559.
  • 25
    Anderson JW, Greenway FL, Fujioka K et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res 2002;10:633641.
  • 26
    Vivtrol (naltrexone) [package insert]. Alkermes: Cambridge, MA, 2009.
  • 27
    Weinsier RL, Ullmann DO. Gallstone formation and weight loss. Obes Res 1993;1:5156.
  • 28
    Kolotkin RL, Norquist JM, Crosby RD et al. One-year health-related quality of life outcomes in weight loss trial participants: comparison of three measures. Health Qual Life Outcomes 2009;7:53.
  • 29
    Foster GD, Makris AP, Bailer BA. Behavioral treatment of obesity. Am J Clin Nutr 2005;82:230S235S.
  • 30
    Hollon SD, DeRubeis RJ. Placebo-psychotherapy combinations: inappropriate representations of psychotherapy in drug-psychotherapy comparative trials. Psychol Bull 1981;90:467477.
  • 31
    Fabricatore AN, Wadden TA, Moore RH et al. Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis. Obes Rev 2009;10:333341.
  • 32
    Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg C. Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med 2001;161:218227.